makinezmoney
3 years ago
$IPHA: Presentation DETAILS today.
Monalizumab:
Title: COAST: an open-label, randomised, phase 2 platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, Stage III NSCLC
Date and time: September 17, 2021, at 2:20 p.m. CEST
Presentation number: LBA42
Alexandre Martinez-Marti (Barcelona, Spain) will deliver the presentation.
ANKET:
Title: Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers
Date and time: September 18, 2021 at 1:30 p.m. CEST
Presentation number: 1O
Professor Eric Vivier, DVM, Chief Scientific Officer of Innate Pharma, will deliver the presentation.
About Monalizumab:
Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
GO $IPHA